There is a lack of evidence to guide treatment decisions in localized diseases. Cotrimoxazole may be used for remission induction in upper airway disease in WG; however, in patients with persistent, localized WG, medium- to highly-potent immunosuppression seems required as cotrimoxazole was not sufficient to control disease activity in a significant proportion of patients.
Methotrexate (MTX) has been shown to be effective in inducing remission in GPA/MPA with a non-organ threatening disease (early systemic disease) in several trials including one controlled trial (NORAM, non-renal alternative treatment with MTX).
Apart from these medicines, In December 2017, the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.
View @ Vasculitis Market Disease
In September 2019, Genentech announced that the US FDA approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of GPA and MPA in pediatric patients 2 years of age and older.
Treatment of AAV has evolved, and with currently available immunosuppressive therapy, up to 85–90% of patients will achieve remission. Tailored therapy that circumvents most of the toxicity associated with care should be the goal. In addition to disease-specific therapy, key management concepts for all patients include prophylaxis and monitoring for conditions (infections).
Enormous progress has been made in the understanding of the etiopathogenesis of the AAV. It has contributed to improvements in early diagnosis, treatment, and even secondary prevention of these severe diseases. The combined efforts of the international community in the field of ANCA-associated vasculitis set the stage for further improvements in the near future, of benefit for patients suffering from AAV.
View @ Vasculitis Market Drugs
Concerning diagnosis and follow-up, sensitive biomarkers that reflect disease activity, also during smoldering disease, are needed. In the field of aetiopathogenesis, genetic and epigenetic studies are being performed not only directed at the autoimmune response but also at the expression of, possibly modified, autoantigens. Environmental factors, in particular microbial factors, are also being explored, which will enable an analysis of gene-environment interactions in the AAV, thus, elucidating their aetiopathogenesis further.
The dynamics of the Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world and also expects the launch of emerging therapies during the forecast period of 2021–2030. Companies across the globe are working towards the development of new treatment therapies for Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis.
Read @ Vasculitis Market Companies
The Vasculitis Market growth rate is attributed to the rising incidences of metabolic disorders and circulatory diseases such as peripheral arterial disease (PAD) and high demand for minimally invasive procedures.
People might have general symptoms, such as fever or fatigue, followed by other symptoms depending on which organs are affected, to confirm diagnosis i.e.
From recent innovations, which embed the introduction of innovative ideas such as use of sequential Magnetic Resonance Imaging magnetic Resonance Angiography (MRIMRA) to the high demand for minimally invasive procedures, better healthcare infrastructure, which anticipated to provide better results to the physicians and allow them to work more efficiently, thereby propelling the Vasculitis Market growth during the forecast period 2020-2025.
People who have mild vasculitis find relief with over-the-counter pain or anti-inflammatory medicines, such as acetaminophen, aspirin, ibuprofen or naproxen is anticipated to further expand the segmental market over the projection period of 2020-2025.
By Geography - Segment AnalysisNorth America dominated the Vasculitis Market with a share of 38% in 2019.
North America remains the largest market of Vasculitis owing to the rising prevalence of large vessel vasculitis, presence of key pharmaceutical companies and the existence of advanced healthcare facilities continue to expand its market.
Vasculitis, a group of diseases, causes inflammation in the blood vessels and results in weakening, thickening, narrowing or scarring of blood vessels.
The causes of vasculitis are generally unknown.
The types of vasculitis are categorized based on the location and size of the affected blood vessels.
Following are the different types of vasculitis based on the size of affected blood vessels:
Small vessel: Churg–Strauss syndrome, Behçet’s syndrome, cutaneous vasculitis, Henoch–Schönlein purpura, Granulomatosis with polyangiitis, microscopic polyangiitis, Golfer’s vasculitis, cryoglobulinemia
Medium vessel: Cutaneous vasculitis, Buerger’s disease, polyarteritis nodosa, Kawasaki disease
